ESR1 and breast cancer: Given the growing body of evidence showing the crucial role of DLL1 in the aggressive phenotypes of this BC type and its association with high mortality in BC patients, Dl1.72 may prove to be a promising tool for clinical development of a treatment for patients with aggressive ER+ BCs, as well as for drug-resistant ER+ BCs.